ATE304522T1 - Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten - Google Patents
Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivatenInfo
- Publication number
- ATE304522T1 ATE304522T1 AT01928832T AT01928832T ATE304522T1 AT E304522 T1 ATE304522 T1 AT E304522T1 AT 01928832 T AT01928832 T AT 01928832T AT 01928832 T AT01928832 T AT 01928832T AT E304522 T1 ATE304522 T1 AT E304522T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- amyloid
- aminoindanderivates
- inhibiting
- protein aggregation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000037259 Amyloid Plaque Diseases 0.000 title abstract 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title abstract 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000001514 detection method Methods 0.000 title 1
- 230000004845 protein aggregation Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
- C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20199600P | 2000-05-04 | 2000-05-04 | |
| PCT/US2001/013254 WO2001083425A1 (en) | 2000-05-04 | 2001-04-25 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE304522T1 true ATE304522T1 (de) | 2005-09-15 |
Family
ID=22748150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01928832T ATE304522T1 (de) | 2000-05-04 | 2001-04-25 | Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6949575B2 (de) |
| EP (1) | EP1284958B1 (de) |
| JP (1) | JP2003531883A (de) |
| AT (1) | ATE304522T1 (de) |
| AU (1) | AU2001255646A1 (de) |
| BR (1) | BR0110519A (de) |
| CA (1) | CA2405611A1 (de) |
| DE (1) | DE60113407T2 (de) |
| ES (1) | ES2248315T3 (de) |
| MX (1) | MXPA02009948A (de) |
| WO (1) | WO2001083425A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027939A1 (en) * | 2003-08-21 | 2005-03-31 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| JP2010518064A (ja) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｄおよび関連状態の治療のためのピペラジン誘導体 |
| JP2009084254A (ja) * | 2007-10-03 | 2009-04-23 | Sumitomo Chemical Co Ltd | アミロイドβタンパク質の蓄積を抑制するための医薬組成物 |
| US9217024B2 (en) | 2007-12-18 | 2015-12-22 | Acumen Pharmaceuticals, Inc. | ADDL receptor polypeptides, polynucleotides and host cells for recombinant production |
| US10196700B2 (en) | 2009-03-24 | 2019-02-05 | University Of Chicago | Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes |
| EP2412020B1 (de) | 2009-03-24 | 2020-09-30 | University Of Chicago | Schiebe- und schneidevorrichtung und entsprechende verfahren |
| US9447461B2 (en) | 2009-03-24 | 2016-09-20 | California Institute Of Technology | Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes |
| US9464319B2 (en) | 2009-03-24 | 2016-10-11 | California Institute Of Technology | Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes |
| CA2870999A1 (en) | 2012-04-20 | 2013-10-24 | SlipChip, LLC | Fluidic devices and systems for sample preparation or autonomous analysis |
| WO2013159116A1 (en) | 2012-04-20 | 2013-10-24 | University Of Chicago | Fluidic devices for biospecimen preservation |
| US9803237B2 (en) | 2012-04-24 | 2017-10-31 | California Institute Of Technology | Slip-induced compartmentalization |
| SI2915804T1 (sl) | 2012-10-31 | 2019-06-28 | Fujifilm Toyama Chemical Co., Ltd. | Novi derivati aminov ali njihove soli kot inhibitorji TNF ALFA |
| AU2016308189B2 (en) * | 2015-08-18 | 2021-03-11 | The Regents Of The University Of California | Nitroxide containing amyloid binding agents for imaging and therapeutic uses |
| US11028051B2 (en) * | 2016-12-13 | 2021-06-08 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| GB8707123D0 (en) * | 1987-03-25 | 1987-04-29 | Pfizer Ltd | Antiarrhythmic agents |
| US5280032A (en) | 1989-02-14 | 1994-01-18 | Toyama Chemical Co., Ltd. | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same |
| EP0535496A1 (de) | 1991-09-25 | 1993-04-07 | Hoechst-Roussel Pharmaceuticals Incorporated | (1-Indanon-2-yl)Methylpiperidine, Zwischenprodukte und Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| IL99759A (en) * | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| IL106877A (en) | 1992-09-10 | 1998-03-10 | Lilly Co Eli | Rodinin derivatives for use as drugs for the treatment of Alzheimer's disease |
| US6001331A (en) | 1996-01-24 | 1999-12-14 | Warner-Lambert Company | Method of imaging amyloid deposits |
| SE9802360D0 (sv) * | 1998-07-01 | 1998-07-01 | Wikstroem Hakan Vilhelm | New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins ((basic)-N-substituted and (basic)-N,N-disubstituted derivatives of 2,6-diamino-thiazolo(4,5-f)indan and 2,7-di-amino-thiazolo(4,5-g)tetralin |
-
2001
- 2001-04-25 BR BR0110519-1A patent/BR0110519A/pt not_active IP Right Cessation
- 2001-04-25 WO PCT/US2001/013254 patent/WO2001083425A1/en active IP Right Grant
- 2001-04-25 MX MXPA02009948A patent/MXPA02009948A/es unknown
- 2001-04-25 ES ES01928832T patent/ES2248315T3/es not_active Expired - Lifetime
- 2001-04-25 JP JP2001580856A patent/JP2003531883A/ja active Pending
- 2001-04-25 AU AU2001255646A patent/AU2001255646A1/en not_active Abandoned
- 2001-04-25 EP EP01928832A patent/EP1284958B1/de not_active Expired - Lifetime
- 2001-04-25 CA CA002405611A patent/CA2405611A1/en not_active Abandoned
- 2001-04-25 US US10/275,351 patent/US6949575B2/en not_active Expired - Fee Related
- 2001-04-25 DE DE60113407T patent/DE60113407T2/de not_active Expired - Fee Related
- 2001-04-25 AT AT01928832T patent/ATE304522T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001255646A1 (en) | 2001-11-12 |
| MXPA02009948A (es) | 2003-02-12 |
| US6949575B2 (en) | 2005-09-27 |
| EP1284958B1 (de) | 2005-09-14 |
| CA2405611A1 (en) | 2001-11-08 |
| BR0110519A (pt) | 2003-04-08 |
| DE60113407T2 (de) | 2006-06-29 |
| JP2003531883A (ja) | 2003-10-28 |
| US20030220382A1 (en) | 2003-11-27 |
| ES2248315T3 (es) | 2006-03-16 |
| WO2001083425A1 (en) | 2001-11-08 |
| DE60113407D1 (de) | 2005-10-20 |
| EP1284958A1 (de) | 2003-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE304522T1 (de) | Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten | |
| EA200101133A1 (ru) | Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина | |
| EA200200976A1 (ru) | Способ лечения или ингибирования полипов ободочной кишки | |
| JO2262B1 (en) | Benzodiazepine derivatives | |
| DE60226912D1 (de) | Chinolin- und Chianzolinderivate zur Behandlung von Tumoren | |
| DE602004011255D1 (de) | Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit | |
| ATE468109T1 (de) | Liposomale abgabe von verbindungen auf vitamin-e- basis | |
| ATE282623T1 (de) | Verfahren und verbindungen für die hemmung von mrp1 | |
| TR200103551T2 (tr) | Amiloid protein birikimini önleme ve amiloid tortularını görüntüleme metodu | |
| DE602004020730D1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
| ATE402185T1 (de) | Verfahren für fluorcytidinderivate | |
| ATE326964T1 (de) | Aminosäurederivate zur behandlung der alzheimer- krankheit | |
| ATE239741T1 (de) | Derivate der phosphonsäure zur inhibierung von carboxypeptidase b | |
| DE60038902D1 (de) | Verwendung von prostanoid-ep4-rezeptor-antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten | |
| DE60212757D1 (de) | Verfahren zur Verwendung von Pyrrolederivaten gegen Zwangsstörungen | |
| TR200103561T2 (tr) | Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları | |
| ATE271551T1 (de) | Verfahren zur herstellung von n-(1-(s)- ethoxycarbonyl-3-phenylpropyl)-l-alanin-n- carboxyanhydrid | |
| DE69330465D1 (de) | Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4-aza-5 alpha-androst-1-en-3-one | |
| DE69821142D1 (de) | Verwendung von prostanoiden-antagonisten zur bhandlung von primären kopfschmerzen | |
| ATE312086T1 (de) | Phenoxazinanaloge zur behandlung von amyloidose | |
| ATE513824T1 (de) | Verfahren zur herstellung von isothiocyanato-2,2- difluorbenzo-(1,3)-dioxolen | |
| DE69916577D1 (de) | Azetidincarboxamid-derivate zur behandlung von zns störungen | |
| ATE225660T1 (de) | Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz | |
| DE602004018121D1 (de) | Verwendung von alpha2-adrenorezeptor antagonisten zur behandlung von epilepsie | |
| TH60792A (th) | อนุพันธ์ 4,5-ไดไฮโดร-1h-ไพราโซลที่มี cb1-แอนแทกโกนีสทิค แอคทิวิทีอย่างมาก |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |